Daily Leader
12:00 p.m.: Morning Hour
2:00 p.m.: Legislative Business

Unlimited “One Minutes”
6:30 p.m. 7:00 p.m.
**Following one minute speeches, the House is expected to recess until approximately 4:45 p.m.  At that time, the House will reconvene and consider the bills listed for consideration under suspension of the Rules. Any recorded votes requested will be postponed until 6:30 p.m.

Suspensions (7 bills)
  1. S. 324 – State Veterans Home Adult Day Health Care Improvement Act of 2017 (Sen. Hatch – Veterans’ Affairs)
  2. H.R. 4465 – Endangered Fish Recovery Programs Extension Act of 2017 (Rep. Curtis – Natural Resources)
  3. H.R. 1800 – To direct the Secretary of Agriculture to transfer certain Federal land to facilitate scientific research supporting Federal space and defense programs, as amended (Rep. Bishop (UT) – Natural Resources)
  4. H.R. 3469 – To designate the bridge located in Blount County, Tennessee, on the Foothills Parkway (commonly known as "Bridge 2") as the "Dean Stone Bridge" (Rep. Duncan (TN) – Natural Resources)
  5. H.R. 4266 – Acadia National Park Boundary Clarification Act, as amended (Rep. Poliquin – Natural Resources)
  6. H.R. 1350 – To modify the boundary of Voyageurs National Park in the State of Minnesota, and for other purposes  (Rep. Nolan – Natural Resources)
  7. H.R. __ – Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (Rep. Fitzpatrick – Energy and Commerce).  This bill, posted just before midnight on Friday night without committee action, threatens to undermine the drug development process and subject patients to serious risk of harm.  Proponents of the bill argue that it will enable seriously ill patients to access unapproved, experimental drugs that could be potentially life-saving.  However, the FDA already has an “expanded access” program in place to enable terminally ill patients to access investigational drugs.  Under the expanded access program, 99.7% of all expanded access requests for patients with immediately life-threatening illnesses are approved by the FDA. Often when patients are denied access to these treatments it is due to the lack of availability of the drug or a pharmaceutical company’s concern about dangerous side effects. This bill will do nothing to compel manufacturers to provide drugs to these patients.

    This bill would also weaken FDA’s ability to oversee adverse events or other clinical outcomes from the use of an investigational drug and provide broad liability protections for manufacturers and health care providers —leaving patients with no recourse in the case of an adverse event. This unnecessary legislation ultimately seeks to undermine the FDA’s authority to ensure safety and efficacy in the nation’s drug supply while providing false hope to patients.  

The GOP Leadership has announced the following schedule for Wednesday, March 14: The House will meet at 12:00 p.m. for legislative business.  The House is expected to consider H.R. 1116 – TAILOR Act of 2017 (Rep. Tipton – Financial Services) (Subject to a Rule).  The House is also expected to begin consideration of H.R. 4545 – Financial Institutions Examination Fairness and Reform Act (Rep. Tipton – Financial Services) (Subject to a Rule) and H.R. 4263 – Regulation A+ Improvement Act of 2017 (Rep. MacArthur – Financial Services) (Subject to a Rule).  Lastly, the House is expected to consider bills listed for consideration under suspension of the Rules.
“The U.S. recorded a $215 billion budget deficit in February -- its biggest in six years -- as revenue declined. Fiscal income dropped to $156 billion, down 9 percent from a year earlier… the Treasury Department said on Monday. The deficit for the fiscal year that began in October widened to $391 billion, compared with a $351 billion shortfall the same period a year earlier, according to the Treasury report. The data underscore concerns by some economists that Republican tax cuts enacted this year could increase the U.S. government debt load, which has surpassed $20 trillion. The tax changes are expected to reduce federal revenue by more than $1 trillion over the next decade…”
    -     Bloomberg, 3/12/2018